Table 3 Comparison of post hoc exploratory secondary outcomes between the haloperidol and placebo group
Outcome | Haloperidol (n = 65) | Placebo (n = 67) | Adjusted relative risk (95% CI)a | p value |
|---|---|---|---|---|
No. of days with study drug, median (IQR) | 4 (3–8) | 6 (3–9) | 0.96 (0.79–1.16) | 0.66 |
No. of delirium days, median (IQR) | 3 (2–6.5) | 3 (2–5) | 1.05 (0.81–1.37) | 0.722 |
No. of coma days, median (IQR) | 0 (0–2) | 0 (0–1) | 1.5 (0.85–2.66) | 0.164 |
Agitation (RASS > 1), n (%) | 25 (39) | 30 (45) | OR: 0.84 (0.4–1.75) | 0.638 |
No. of days, median (IQR) | 0 (0–1) | 0 (0–1) | 0.77 (0.43–1.39) | 0.388 |
Hallucinations/delusions, n (%) | 55 (85) | 51 (76) | OR: 1.75 (0.72–4.4) | 0.220 |
No. of days, median (IQR) | 2 (1–3) | 3 (1–4.5) | 0.74 (0.53–1.03) | 0.075 |
Removal of urinary catheter, n (%) | 5 (8) | 9 (13) | OR: 0.48 (0.14–1.52) | 0.226 |
Physical restraint, n (%) | 48 (74) | 48 (72) | OR: 1.19 (0.54–2.64) | 0.660 |
(Almost) fell or stepped out of bed, n (%) | 6 (9) | 18 (27) | OR: 0.32 (0.11–0.84) | 0.026 |